Table 3 Clinical and demographic characteristics of patients receiving different CMS dosage regimens
Variable | Colistin dosage regimen, n (%) | P | |||
|---|---|---|---|---|---|
1 million IU/8 h (n = 28) | 2 million IU/8 h (n = 42) | 3 million IU/8 h (n = 16) | Other doses (n = 16) | ||
Age (yrs) | 74 (24–85) | 67 (27–91) | 55.5 (28–74) | 73 (42–85) | 0.023 |
N° (%) of male patients | 22 (78.6) | 32 (76.2) | 14 (87.5) | 11 (68.8) | 0.64 |
Charlson score | 4.8 ± 2.8 | 4.36 ± 2.6 | 3.7 ± 2.5 | 4.8 ± 2.1 | 0.41 |
N° (%) of severe sepsis | 11 (39.3) | 22 (52.4) | 9 (56.3) | 6 (37.5) | 0.5 |
N° (%) septic shock | 1 (3.6) | 3 (7.1) | 2 (12.5) | 2 (12.5) | 0.63 |
APACHE II | 12.8 ± 6.7 | 11.9 ± 4.6 | 11.5 ± 4.45 | 13.7 ± 7.5 | 0.28 |
1CKD at baseline | 12 (42.9) | 7 (16.7) | 1 (6.3) | 11 (68.8) | <0.0001 |
Colistin dose (in 2CBA) in mg/kg/day (3IBW) | 1.48 ± 0.3 | 2.9 ± 0.37 | 4.38 ± 0.9 | 1.54 ± 0.82 | <0.0001 |
4Cmin | 0.71 (0.2-2.01) | 1.14 (0.11-5) | 1.84 (0.45-5.99) | 1.5 (0.16-3.02) | 0.003 |
5Cmax | 0.65 (0.24-1.99) | 1.13 (0.15-5) | 1.84 (0.5-6.62) | 1.5 (0.16-3.7) | 0.001 |
6CMS cumulative dose | 58.5 ± 50.6 | 111.7 ± 85.9 | 171.5 ± 105.7 | 73.9 ± 111.3 | <0.0001 |
CMS duration treatment | 20 ± 16.5 | 19.5 ± 15.6 | 19.25 ± 8 | 19.2 ± 19.8 | 0.41 |
Concomitant antibiotics | 15 (53.6) | 23 (54.8) | 10 (62.5) | 8 (50) | 0.9 |
7AKI at day 7 | 5 (17.9) | 11 (26.2) | 7 (43.8) | 3 (18.8) | 0.25 |
AKI at 8EOT | 14 (50) | 21 (50) | 9 (56.3) | 6 (37.5) | 0.7 |
Clinical response | 25 (89.3) | 32 (76.2) | 11 (68.8) | 11 (68.8) | 0.3 |